Material produced by Kepler Trust Intelligence should be considered as factual information only and not an indication as to the desirability or appropriateness of investing in the security discussed.
Please see the important information by following this link or at the bottom of the page.
Woodford Patient Capital (WPCT) has a concentrated portfolio of early-stage unquoted and quoted companies, focused on technology and healthcare, with high return potential and high levels of stock-specific risk. It is managed by Neil Woodford, one of the most high-profile fund managers in the country. The trust does not pay a dividend.
Neil focuses on picking businesses that he believes have the chance to be successful through the use of new technologies and in whose management teams he has faith. The trust is a pure stock-picking play, with the manager paying no heed to sector or geographic concentration. The drivers of the companies should be secular developments in their fields, and fundamentally global in scope.
The portfolio has become highly concentrated, although position weightings are no longer being published since the open-ended Woodford Equity Income fund has been gated. Most of the portfolio is now in unquoted companies.
Since launch in 2015, the NAV total return performance has been disappointing, with the trust losing 20%, while the FTSE All Share has returned 22.5% over the same period. Since June 2019, WPCT has been affected by the issues in the wider Woodford Investment Management (WIM) business that have led it to fall onto a discount of 45%. One of the fears is that the manager may have to sell unquoted stocks in the open-ended fund which are also held in WPCT, and if he is seen as a forced seller or if this is a disadvantageous time in the development of the companies, this could lead to mark downs to the trust’s NAV.
We note that one potentially attractive feature for investors is that WPCT has no annual management fee. Although there is a performance fee, it won’t be payable until the NAV reaches 146p – an almost 50% uplift to its current level. This means that investors will only pay the 0.18% ongoing charges until that mark has been passed. The possibility of a change of manager has been discussed by the board, and so it is worth noting that these advantageous fee arrangements might not be retained should a new manager be appointed.
Kepler Trust Intelligence is a website owned and managed by Kepler Partners LLP. Material produced by Kepler Trust Intelligence should be considered a marketing communication, and is not independent research.
This report has been issued by Kepler Partners LLP for communication only to eligible counterparties and professional clients as defined by the Financial Conduct Authority. Its contents are not directed at, are not to be communicated to, may not be suitable for and must not be relied on by retail clients.
The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. Persons who access this information are required to inform themselves and to comply with any such restrictions.
The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research. The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.
This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.
Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm’s internal rules.
Past performance is not necessarily a guide to the future. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. Independent financial advice should be taken before entering into any financial transaction. This website is published solely for informational purposes and has no regard to the specific investment objectives, financial situation or particular needs of any person.
PLEASE SEE ALSO OUR TERMS AND CONDITIONS
A copy of the firm’s conflict of interest policy is available on request.
Kepler Partners LLP is a limited liability partnership registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.
Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority.
Fund History: Woodford Patient Capital Trust
Invesco UK Equities managers Jonathan Brown and Robin West discuss three stocks that have fulfilled their investment thesis over the last few years...
Amid the recent revival for emerging markets, investors have remained focused on Asian markets. Should they be looking further afield to Latin America? Ed Kuczma, co-manager of the BlackRock Latin ...
For several years, quality as an investing style has dominated, outperforming both value and growth. We examine why the case for quality remains strong and the importance of taking an active approach…
We examine the AIC's revised sector classifications and discuss whether further improvements could be made...